These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Han KH; Kudo M; Ye SL; Choi JY; Poon RT; Seong J; Park JW; Ichida T; Chung JW; Chow P; Cheng AL Oncology; 2011; 81 Suppl 1():158-64. PubMed ID: 22212951 [TBL] [Abstract][Full Text] [Related]
13. Assessment of the treatment response of HCC. Kim KW; Lee JM; Choi BI Abdom Imaging; 2011 Jun; 36(3):300-14. PubMed ID: 21279353 [TBL] [Abstract][Full Text] [Related]
15. Chemoembolization and bland embolization: a critical appraisal. Befeler AS Clin Liver Dis; 2005 May; 9(2):287-300, vii. PubMed ID: 15831274 [TBL] [Abstract][Full Text] [Related]
17. Established and emerging therapies for hepatocellular carcinoma. Cicinnati VR; Sotiropoulos GC; Beckebaum S Minerva Med; 2010 Dec; 101(6):405-18. PubMed ID: 21196900 [TBL] [Abstract][Full Text] [Related]
18. Pre-transplant therapy for hepatocellular carcinoma is associated with a lower recurrence after liver transplantation. Lao OB; Weissman J; Perkins JD Clin Transplant; 2009; 23(6):874-81. PubMed ID: 19453644 [TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. Cescon M; Cucchetti A; Ravaioli M; Pinna AD J Hepatol; 2013 Mar; 58(3):609-18. PubMed ID: 23041304 [TBL] [Abstract][Full Text] [Related]